When severe malaria is suspected in children, WHO recommends pre-treatment with a single rectal dose of artesunate before referral to an appropriate facility. This was an individually randomized, open-label, 2-arm, cross-over clinical trial in 83 Congolese children with severe falciparum malaria, to characterize the pharmacokinetics of rectal artesunate. At admission, children received a single dose of rectal artesunate (10 mg/kg) followed 12 hours later by intravenous artesunate (2.4 mg/kg) or the reverse order. All children also received standard doses of intravenous quinine. Artesunate and dihydroartemisinin were measured at eleven fixed intervals, following 0- and 12-hour drug administrations. Clinical, laboratory and parasitological parameters were measured.
Seasonal malaria chemoprevention (SMC) aims to prevent malaria in children during the high malaria transmission season. The Achieving Catalytic Expansion of SMC in the Sahel (ACCESS-SMC) project sought to remove barriers to the scale-up of SMC in seven countries in 2015 and 2016. We evaluated the project, including coverage, effectiveness of the intervention, safety, feasibility, drug resistance, and cost-effectiveness.
This study intended to inform future programming in relation to the role that Information – Education – Communication (IEC) could play in enhancing this continuum of care. It hypothesized that community exposure to targeted IEC would increase early presentation by the caregiver at the village health clinic (VHC) for Rectal Artesunate (RAS) and the caregiver acceptance of RAS; and that community health worker (CHW/HSA) exposure to a targeted toolkit would increase appropriate assessment, administration of RAS and referral, and in turn enhance prompt compliance with referral instructions among caregivers.
This study aimed to identify existing gaps in knowledge about severe malaria case management in Angola by collecting information at different health service levels and through different study populations
For related malaria (B50), one of the outstanding host factors for the development of severe disease is the ABO blood group of malaria patients, where blood group O reduces the probability of severe disease as compared to individuals of groups A, B, or AB.
Africa needs to be prepared to deal with COVID-19, given the infectious potential of the disease and its capacity to undermine malaria control efforts.
